Kay Tanita

Kay Tanita

Auto-generated profile, based on publicly available information

Kay Tanita

Graduate School of Medical and Dental Sciences, Institute of Science Tokyo 2 Department of Pediatrics and Developmental Biology Tokyo

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CCChelisa Cardinez
Chelisa Cardinez
BMBahar Miraghazadeh
Bahar Miraghazadeh
KTKay Tanita
Kay Tanita
ESElizabeth da Silva
Elizabeth da Silva
AHAkihiro Hoshino
Akihiro Hoshino
MCMatthew C. Cook
Matthew C. Cook
Genetic mutations account for many devastating early onset immune deficiencies. In contrast, less severe and later onset immune diseases, including in patients with no prior family history, remain poorly understood. Whole exome sequencing in two cohorts of such patients identified a novel heterozygous de novo IKBKB missense mutation (c.607G>A) in two separate kindreds in whom probands presented with immune dysregulation, combined T and B cell deficiency, inflammation, and epithelial defects. IKBKB encodes IKK2, which activates NF-κB signaling. IKK2V203I results in enhanced NF-κB signaling, as well as T and B cell functional defects. IKK2V203 is a highly conserved residue, and to prove causation, we generated an accurate mouse model by introducing the precise orthologous codon change in Ikbkb using CRISPR/Cas9. Mice and humans carrying this missense mutation exhibit remarkably similar cellular and biochemical phenotypes. Accurate mouse models engineered by CRISPR/Cas9 can help characterize novel syndromes arising from de novo germline mutations and yield insight into pathogenesis.

1 March 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DPDaniel Petersheim
Daniel Petersheim
MMMichel J. Massaad
Michel J. Massaad
SLSaetbyul Lee
Saetbyul Lee
ASAlessia Scarselli
Alessia Scarselli
CCCaterina Cancrini
Caterina Cancrini
RGRaif S. Geha
Raif S. Geha

1 October 2018 in Clinical Immunology
Verified
Journal Article
Closed access
AHAkihiro Hoshino
Akihiro Hoshino
KTKay Tanita
Kay Tanita
KKKenji Kanda
Kenji Kanda
KIKen-Ichi Imadome
Ken-Ichi Imadome
YSYoshiaki Shikama
Yoshiaki Shikama
HKHirokazu Kanegane
Hirokazu Kanegane

28 April 2025 in Journal of Human Immunity
Verified
Journal Article
Open access
HKHirokazu Kanegane
Hirokazu Kanegane
KTKay Tanita
Kay Tanita
MNMadoka Nishimura
Madoka Nishimura
DTDan Tomomasa
Dan Tomomasa
KIKento Inoue
Kento Inoue
HOHans D. Ochs
Hans D. Ochs
Discovered >70 years ago by Ogden Bruton, X-linked agammaglobulinemia (XLA), characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and peripheral blood B-cell deficiency, is among the best-established inborn errors of immunity (IEIs) and one of the most well-documented single types of IEIs, the incidence of which is estimated to be between 1:100,000 and 1:200,000. However, although the pathogenesis of XLA is well understood, several issues remain open for discussion. In this review, we describe several unresolved issues, including noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, noninfectious neurodegeneration, renal involvement, and malignancies. The primary treatment for XLA, immunoglobulin replacement therapy, administered either intravenously or subcutaneously, has remained unchanged since its discovery. Allogeneic hematopoietic cell transplantation has been successful in some XLA patients, but there are still few reports. However, it may be considered as a treatment option in the future. Given that XLA is one of the most common types of IEIs, resolving these issues is a priority.

7 April 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
TKTakao Karasawa
Takao Karasawa
KKKo Kudo
Ko Kudo
KTKay Tanita
Kay Tanita
YTYoshihiro Takahashi
Yoshihiro Takahashi
HKHirokazu Kanegane
Hirokazu Kanegane
KTKiminori Terui
Kiminori Terui